{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:10:43Z","timestamp":1761718243113,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.biopha.2012.10.018","type":"journal-article","created":{"date-parts":[[2012,11,19]],"date-time":"2012-11-19T16:15:37Z","timestamp":1353341737000},"page":"164-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity"],"prefix":"10.1016","volume":"67","author":[{"given":"Yan-bo","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-yang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-su","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2012.10.018_bib0005","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1126\/science.279.5349.377","article-title":"Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model","volume":"279","author":"Arap","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.biopha.2012.10.018_bib0010","first-page":"722","article-title":"Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis","volume":"60","author":"Pasqualini","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2012.10.018_bib0015","first-page":"867","article-title":"Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells","volume":"62","author":"Curnis","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2012.10.018_bib0020","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood.V97.3.652","article-title":"CD13\/APN is activated by angiogenic signals and is essential for capillary tube formation","volume":"97","author":"Bhagwat","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2012.10.018_bib0025","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/81183","article-title":"Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)","volume":"18","author":"Curnis","year":"2000","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.biopha.2012.10.018_bib0030","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1158\/0008-5472.CAN-04-4282","article-title":"Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counter regulatory mechanisms","volume":"65","author":"Curnis","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2012.10.018_bib0035","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/12469","article-title":"Anti-cancer activity of targeted pro-apoptotic peptides","volume":"5","author":"Ellerby","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.biopha.2012.10.018_bib0040","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0006-2952(01)00928-5","article-title":"A doxorubicin-CNGRC-peptide conjugate with prodrug properties","volume":"63","author":"van","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.biopha.2012.10.018_bib0045","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2011.05.022","article-title":"APN\/CD13-targeting as a strategy to alter the tumor accumulation of liposomes","volume":"154","author":"Dunne","year":"2011","journal-title":"J Control Release"},{"key":"10.1016\/j.biopha.2012.10.018_bib0050","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jconrel.2009.05.030","article-title":"NGR-modified micelles enhance their interaction with CD13-over expressing tumor and endothelial cells","volume":"139","author":"Wang","year":"2009","journal-title":"J Control Release"},{"key":"10.1016\/j.biopha.2012.10.018_bib0055","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jconrel.2011.02.027","article-title":"Enhanced gene transfection efficiency in CD13-positive vascular endothelial cells with targeted poly(lactic acid)-poly(ethylene glycol) nanoparticles through caveolae-mediated endocytosis","volume":"151","author":"Liu","year":"2011","journal-title":"J Control Release"},{"key":"10.1016\/j.biopha.2012.10.018_bib0060","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/j.peptides.2005.03.049","article-title":"Aminopeptidase N\/CD13 targeting fluorescent probes: synthesis and application to tumor cell imaging","volume":"26","author":"Zhang","year":"2005","journal-title":"Peptides"},{"key":"10.1016\/j.biopha.2012.10.018_bib0065","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.7164\/antibiotics.42.1294","article-title":"A new macromolecular antitumor antibiotic, C-1027. III. Antitumor activity","volume":"42","author":"Zhen","year":"1989","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.biopha.2012.10.018_bib0070","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/187152008783497055","article-title":"Enediyne anticancer antibiotic lidamycin: chemistry, biology and pharmacology","volume":"8","author":"Shao","year":"2008","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.biopha.2012.10.018_bib0075","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1021\/bi00072a008","article-title":"Some characteristics of DNA strand scission by macromolecular antitumor antibiotic C-1027 containing a novel enediyne chromophore","volume":"32","author":"Sugiura","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2012.10.018_bib0080","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1006\/bbrc.1995.1329","article-title":"Induction of apoptosis by enediyne antitumor antibiotic C1027 in HL-60 human promyelocytic leukemia cells","volume":"208","author":"Jiang","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.biopha.2012.10.018_bib0085","first-page":"265","article-title":"Preparation of genetically engineered lidamycin and its antitumor activity","volume":"35","author":"Ru","year":"2010","journal-title":"Chinese J Antibiot"},{"key":"10.1016\/j.biopha.2012.10.018_bib0090","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/1078-0432.CCR-09-2699","article-title":"A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity","volume":"16","author":"Guo","year":"2010","journal-title":"Clin\u00a0Cancer\u00a0Res"},{"key":"10.1016\/j.biopha.2012.10.018_bib0095","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11427-007-0058-5","article-title":"Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin","volume":"50","author":"Miao","year":"2007","journal-title":"Sci China C Life Sci"},{"key":"10.1016\/j.biopha.2012.10.018_bib0100","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.canlet.2010.02.020","article-title":"A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice","volume":"295","author":"Zhong","year":"2010","journal-title":"Cancer Lett"},{"issue":"49","key":"10.1016\/j.biopha.2012.10.018_bib0105","doi-asserted-by":"crossref","first-page":"47891","DOI":"10.1074\/jbc.M207500200","article-title":"Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif","volume":"277","author":"Colombo","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biopha.2012.10.018_bib0110","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.1074\/jbc.M109.044297","article-title":"Critical role of flanking residues in NGR-to-isoDGR transition and CD13\/integrin receptor switching","volume":"285","author":"Curnis","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biopha.2012.10.018_bib0115","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.molimm.2005.10.009","article-title":"Immunogenic\u00a0and\u00a0structural\u00a0properties\u00a0of the Asn-Gly-Arg\u00a0(NGR) tumor neovasculature-homing motif","volume":"43","author":"Di Matteo","year":"2006","journal-title":"Mol Immunol"},{"key":"10.1016\/j.biopha.2012.10.018_bib0120","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jbiotec.2009.09.001","article-title":"Binding capability of the enediyne-associated apoprotein to human tumors and constitution of a ligand oligopeptide-integrated protein","volume":"144","author":"Cai","year":"2009","journal-title":"J Biotechnol"},{"key":"10.1016\/j.biopha.2012.10.018_bib0125","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1016\/j.bmc.2006.01.012","article-title":"Aponeocarzinostatin \u2013 a superior drug carrier exhibiting unusually high endurance against denaturants","volume":"14","author":"Sudhahar","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.biopha.2012.10.018_bib0130","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1021\/jm040790d","article-title":"Design and synthesis of a nitrogen mustard derivative stabilized by apo-neocarzinostatin","volume":"47","author":"Urbaniak","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.biopha.2012.10.018_bib0135","first-page":"602","article-title":"Optimization\u00a0of the\u00a0assembly\u00a0efficiency\u00a0for\u00a0lidamycin\u00a0chromophore\u00a0bound to its apoprotein: a case study using orthogonal array","volume":"24","author":"Zhong","year":"2011","journal-title":"Biomed Environ Sci"},{"key":"10.1016\/j.biopha.2012.10.018_bib0140","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.7164\/antibiotics.41.1696","article-title":"C-1027-AG, a selective antagonist of the macromolecular antitumor antibiotic C-1027","volume":"41","author":"Otani","year":"1988","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.biopha.2012.10.018_bib0145","first-page":"1503","article-title":"Clinical significance of aminopeptidase N\/CD13 expression in human pancreatic carcinoma","volume":"9","author":"Ikeda","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2012.10.018_bib0150","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1158\/1078-0432.CCR-06-0338","article-title":"Clinical significance of aminopeptidase N in non-small cell lung cancer","volume":"12","author":"Tokuhara","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2012.10.018_bib0155","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1172\/JCI42550","article-title":"CD13 is a therapeutic target in human liver cancer stem cells","volume":"120","author":"Haraguchi","year":"2010","journal-title":"J Clin Invest"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332212001102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332212001102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:50:34Z","timestamp":1760093434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332212001102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0753332212001102"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2012.10.018","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2012.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}